Gilead Sciences, Inc. $GILD Shares Purchased by Artemis Investment Management LLP

Artemis Investment Management LLP increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 54,712 shares of the biopharmaceutical company’s stock after purchasing an additional 6,988 shares during the period. Artemis Investment Management LLP’s holdings in Gilead Sciences were worth $6,715,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GILD. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. Invesco Ltd. lifted its stake in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares during the period. Legal & General Group Plc boosted its holdings in shares of Gilead Sciences by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after acquiring an additional 414,454 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Gilead Sciences by 5.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after acquiring an additional 400,002 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after acquiring an additional 726,101 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $131.65 on Friday. The stock has a market capitalization of $163.41 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 1.74 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $95.29 and a twelve month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a 50-day moving average of $140.49 and a 200 day moving average of $132.45.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is 48.45%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the insider directly owned 128,779 shares of the company’s stock, valued at $18,152,687.84. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at approximately $24,835,883.36. This trade represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 178,640 shares of company stock valued at $26,584,250. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GILD has been the subject of a number of research reports. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, February 11th. TD Cowen increased their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Finally, Jefferies Financial Group assumed coverage on Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.35.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.